Morgan Stanley: Raises Shanghai Fosun Pharmaceutical (02196) revenue forecast, target price of HK$32, and rating of "overweight"
H shares target price of HK$32, rating "hold".
Morgan Stanley released a research report stating that they have raised their revenue forecast for Shanghai Fosun Pharmaceutical (02196) for 2026 to 2028 by 3%, based on the increase in sales of innovative drugs and the expected annual recurring licensing income of approximately 800 million RMB. The bank has set a target price of HK$32 for the H shares and rated it as "hold".
Related Articles
China Merchants Bank's London branch has issued 3 billion yuan worth of notes, which have been approved for trading on the International Securities Market of the London Stock Exchange.
7ROAD (00797) spent 1.7835 million Hong Kong dollars on April 22 to repurchase 2.4 million shares.
MEITU (01357) repurchased 2.32 million shares for HK$10,001.8 million on April 22nd.
China Merchants Bank's London branch has issued 3 billion yuan worth of notes, which have been approved for trading on the International Securities Market of the London Stock Exchange.
7ROAD (00797) spent 1.7835 million Hong Kong dollars on April 22 to repurchase 2.4 million shares.
MEITU (01357) repurchased 2.32 million shares for HK$10,001.8 million on April 22nd.
RECOMMEND
DeepSeek’s $10 Billion Valuation Financing Rumor And Four Layers Of Logical Judgment
21/04/2026
48 Hours Witness AI’s New Battlefield: Alibaba Joins, Tencent Open Sources, Manycore Tech Lists — Has The World Model Reached Its ChatGPT Moment?
21/04/2026
Public Fund Giants Reverse Course With Heavy Hong Kong IPO Cornerstone Allocations Exceeding HK$2.2 Billion Year‑To‑Date
21/04/2026
